<DOC>
	<DOCNO>NCT00200200</DOCNO>
	<brief_summary>The purpose study determine whether addition bevacizumab , hepatic arterial therapy floxuridine ( FUDR ) dexamethasone ( Dex ) ( regional chemotherapy ) , either oxaliplatin CPT-11 , plus 5-fluorouracil leucovorin ( systemic chemotherapy ) increase disease free survival patient undergone liver resection . The patient randomize ( computer generate decision flip coin ) receive , receive bevacizumab addition regional systemic chemotherapy .</brief_summary>
	<brief_title>Hepatic Arterial Infusion With Floxuridine Dexamethasone Combination With Chemotherapy With/Without Bevacizumab Hepatic Metastases From Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Floxuridine</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>History histologically confirm colorectal adenocarcinoma metastatic liver clinical radiographic evidence extrahepatic disease . Confirmation diagnosis must perform MSKCC . Potentially completely resectable hepatic metastasis without current evidence metastatic disease . Abdominal pelvic CT scan chest CT xray within 6 week prior registration . ( MRI abdomen may substitute CT abdomen . ) Lab value within 14 day prior registration : WBC ≥ 3.0 K/uL ANC &gt; 1.5 K/uL Platelets ≥ 75 K/uL Total bilirubin &lt; 1.5 mg/dL INR &lt; 1.5 Creatinine &lt; 2.0 mg/dL HGB ≥ 9 gm/dL Prior chemotherapy acceptable last dose give ≥ 3 week prior registration study . [ Note : chemotherapy give resection liver lesion prior treatment study . ] KPS ≥ 70 % Signed informed consent Patient age must &gt; 18 Prior radiation liver . ( Prior radiation therapy pelvis acceptable complete least 4 week prior registration . ) Active infection , ascites , hepatic encephalopathy . Prior treatment HAI FUDR . Female patient pregnant lactate . Subjects discover ≥1+ proteinuria baseline undergo 24hour urine collection , must adequate collection must demonstrate &lt; 1 g protein/24 hour allow participation study . Patients may receive investigational agent Patients know brain metastasis would confound evaluation neurologic adverse event exclude . Patients history primary CNS tumor , seizure wellcontrolled standard medical therapy , history stroke also exclude . History allergic reaction attribute compound similar chemical biologic composition bevacizumab . Serious nonhealing active wound , ulcer , bone fracture Major surgical procedure , open biopsy significant traumatic injury within 28 day prior Day 1 protocol treatment . ( Surgery perform resect metastatic lesion place pump exclude patient protocol ; Day 1 protocol treatment take place sooner 28 day surgery . ) Current recent use thrombolytic agent . Chronic daily treatment aspirin ( &gt; 325 mg/d ) nonsteroidal antiinflammatory medication know inhibit platelet function . Presence bleed diathesis coagulopathy . History serious systemic disease , include myocardial infarction within last 12 month , uncontrolled hypertension ( blood pressure &gt; 160/110 mmHg medication ) , unstable angina within last 12 month , New York Heart Association ( NYHA ) Grade II great congestive heart failure ( see Appendix C ) , unstable symptomatic arrhythmia require medication ( subject chronic atrial arrhythmia , i. e. atrial fibrillation paroxysmal supraventricular tachycardia eligible ) , peripheral vascular disease ( Grade II great ) . Patients history stroke transient ischemic attack . Presence central nervous system brain metastasis . Patients diagnosis Gilbert 's disease .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>BEVACIZUMAB ( AVASTIN )</keyword>
	<keyword>DEXAMETHASONE</keyword>
	<keyword>FLOXURIDINE</keyword>
	<keyword>FLUOROURACIL</keyword>
	<keyword>IRINOTECAN ( CPT-11 ) CAMPTOSAR</keyword>
	<keyword>LEUCOVORIN</keyword>
	<keyword>OXALIPLATIN</keyword>
	<keyword>Colon</keyword>
	<keyword>Rectal</keyword>
	<keyword>04-086</keyword>
	<keyword>Adjuvant postoperative chemo CLM</keyword>
</DOC>